Louisville is first in Site Selection’s ranking

Despite a tough year, Louisville has earned first place in Site Selection’s annual Ohio River Corridor ranking. The magazine ranks regions that abut the Ohio River by examining corporate facility project data on an overall and per-capita basis during an 18-month period. In the first three quarters of 2020, Louisville has tallied 30 located projects, added 1,253 jobs and represented $253.2 million in new investment.

Groundbreaking virtual golf game to make debut

PinSeeker, a Louisville-based company, is launching a new virtual golf game. The game’s app communicates with a simulator through a QR code. Once it’s communicated, the player can take their swings. In just about a second, it ties together swing and ball speed, accuracy and more. The game goes live in January.

Angel’s Envy moves forward with $6.5 million visitor center

Local bourbon distiller Angel’s Envy will spend $6.5 million on a visitor center expansion. Angel’s Envy Co-Founder and Chief Innovation Officer Wes Henderson told Louisville Business First: “We are thrilled to soon be breaking ground on expanding our Downtown Louisville visitors center. We also look forward to providing economic growth opportunities within our hometown.”

Louisville soars in homebuyer popularity

Technology-powered real estate brokerage firm Redfin has released a report about which cities have soared in popularity with out-of-town homebuyers since the pandemic began. Louisville is number 2 on that list. Louisville Redfin agent Danielle Field said the area has experienced an uptick in people moving in from all around the country, including California, New York, Chicago, Atlanta, Nashville, Phoenix, Austin, Seattle, and Florida.

UofL vice dean participates in Pfizer drug trial

Jon Klein, vice dean for research at the UofL School of Medicine, is a participant in a trial with Pharmaceutical company Pfizer and its collaborator, BioNTech. “While we must wait for the safety data, the news from Pfizer this morning about the effectiveness of their COVID-19 vaccine exceeds all expectations. From my own perspective as a participant in the trial, the two-injection vaccine was not a bad experience and my own adverse effects were mild,” Klein said in a statement.